Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor
Recruiting now · Phase 2
Conditions studied: Advanced Breast Cancer
In brief
Protocol Title: A Phase II open label, umbrella study evaluating the efficacy and safety of Fulvestrant plus DNA damage repair inhibitors in hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor
Key facts
- Study ID
- NCT05536128
- Run by
- Seoul National University Hospital
- People needed
- 64
- Starts
- 2022-12-31
- Expected to finish
- 2025-12-31
- Last updated by the study team
- 2025-04-17
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Seoul National University Hospital — Seoul, South Korea (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.